PULSE BIOSCIENCES INC (PLSE)

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

Bullish Two Hundred Day Moving Average Cross - PLSE

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

PLSE Makes Notable Cross Below Critical Moving Average

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023

Pulse Biosciences just reported results for the fourth quarter of 2023.

PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pulse Biosciences (NASDAQ:PLSE) just reported results for the fourth quarter of...

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

Pulse Biosciences Announces Plans to Initiate a Rights Offering

Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024

Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System

Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study

Oversold Conditions For Pulse Biosciences (PLSE)

Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium

Pulse Biosciences submits market application for cardiac ablation device (NASDAQ:PLSE)

Pulse Biosciences has submitted an application for FDA clearance of CellFX nsPFA Cardiac Clamp, a non-thermal cardiac ablation device. Read more here.

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Pulse Biosciences director buys stock worth $1.11M (NASDAQ:PLSE)

Pulse Biosciences director and 10% owner, Robert W. Duggan, increases his share holding by buying 116,656 shares at $9.54, now holding ~36.87M shares.

Top Buys by Top Brass: Chief Strategy Officer Levinson's $105.1K Bet on PLSE

Pulse Biosciences director Duggan buys shares worth $1.4M - filing (NASDAQ:PLSE)

Pulse Biosciences director Robert Duggan purchases $1.4M worth of company shares in recent insider trading, contributing to 7 total insider trades.

Bag This Bargain Even Cheaper Than Chief Executive Officer Danahy Did

Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

PLSE Crosses Above Key Moving Average Level

Pulse Biosciences Schedules Third Quarter 2023 Financial Results Conference Call for November 13, 2023

Pulse Biosciences Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery